InMed to Participate in Upcoming Investor Conferences in April and May 2022
19 avr. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Announces Management Changes
17 mars 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed to Present at the 34th Annual Roth Conference
08 mars 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
Vancouver, BC, March 08, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica
15 févr. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update
14 févr. 2022 19h34 HE
|
InMed Pharmaceuticals Inc.
Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for...
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022
10 févr. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
19 janv. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands the Company’s rare cannabinoid product portfolio, which also includes...
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
05 janv. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization...
Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s Management Team On January 6, 2022
30 déc. 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization...
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma
20 déc. 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization...